Literature DB >> 26393908

The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1α expression in breast cancer cells.

Chao Shao1, Jingjing Zhang2, Jianhua Fu3, Feihai Ling4.   

Abstract

One of transcription factors of the T-box family, Brachyury has been implicated in tumorigenesis of many types of cancers, regulating cancer cell proliferation, metastasis, invasion and epithelial-to-mesenchymal transition (EMT). However, the role of Brachyury in breast cancer cells has been scarcely reported. The present study aimed to investigate the expression and role of Brachyury in breast cancer. Brachyury expression was analyzed by qRT-PCR and Western blot. The correlations between Brachyury expression and clinicopathological factors of breast cancer were determined. Involvement of EMT stimulation and hypoxia-inducible factor-1α (HIF-1α) expression induction by Brachyury was also evaluated. Moreover, the effect of Brachyury on tumor growth and metastasis in vivo was examined in a breast tumor xenograft model. Brachyury expression was enhanced in primary breast cancer tissues and Brachyury expression was correlated with tumor stage and lymph node metastasis. Hypoxia enhanced Brachyury expression, the silencing of which blocked the modulation effect of hypoxia on E-cadherin and vimentin expression. Brachyury significantly augmented HIF-1alpha expression via PTEN/Akt signaling as well as accelerated cell proliferation and migration in vitro. Additionally, Brachyury accelerated breast tumor xenograft growth and increased lung metastasis in nude mice. In summary, our data confirmed that Brachyury might contribute to hypoxia-induced EMT of breast cancer and trigger HIF-1alpha expression via PTEN/Akt signaling.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachyury; Breast cancer; Epithelial-to-mesenchymal transition; Hypoxia-inducible factor-1α; Tumor xenograft

Mesh:

Substances:

Year:  2015        PMID: 26393908     DOI: 10.1016/j.bbrc.2015.09.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.

Authors:  Duane H Hamilton; Mario Roselli; Claudia Palena; Fiorella Guadagni; Patrizia Ferroni; Leopoldo Costarelli; Francesco Cavaliere; Mariateresa Taffuri
Journal:  Endocr Relat Cancer       Date:  2016-10       Impact factor: 5.678

Review 2.  Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.

Authors:  Duane H Hamilton; Justin M David; Charli Dominguez; Claudia Palena
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

3.  Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Authors:  Sagar R Shah; Justin M David; Nathaniel D Tippens; Ahmed Mohyeldin; Juan C Martinez-Gutierrez; Sara Ganaha; Paula Schiapparelli; Duane H Hamilton; Claudia Palena; Andre Levchenko; Alfredo Quiñones-Hinojosa
Journal:  Cell Rep       Date:  2017-10-10       Impact factor: 9.423

4.  Yi Ai Fang, a traditional Chinese herbal formula, impacts the vasculogenic mimicry formation of human colorectal cancer through HIF-1α and epithelial mesenchymal transition.

Authors:  Fenggang Hou; Wen Li; Qi Shi; Hongjia Li; Shanshan Liu; Shaoqi Zong; Jianlin Ren; Jie Chai; Jian Xu
Journal:  BMC Complement Altern Med       Date:  2016-11-02       Impact factor: 3.659

5.  MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.

Authors:  Saber Imani; Chunli Wei; Jingliang Cheng; Md Asaduzzaman Khan; Shangyi Fu; Luquan Yang; Mousumi Tania; Xianqin Zhang; Xiuli Xiao; Xianning Zhang; Junjiang Fu
Journal:  Oncotarget       Date:  2017-03-28

Review 6.  The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.

Authors:  Saber Imani; Xianqin Zhang; Hossein Hosseinifard; Shangyi Fu; Junjiang Fu
Journal:  Oncotarget       Date:  2017-04-04

7.  Multiple malignant tumors in a patient with familial chordoma, a case report.

Authors:  Nuttavut Sumransub; Paari Murugan; Shelly Marette; Denis R Clohisy; Keith M Skubitz
Journal:  BMC Med Genomics       Date:  2021-08-31       Impact factor: 3.063

8.  Oridonin inhibits VEGF-A-associated angiogenesis and epithelial-mesenchymal transition of breast cancer in vitro and in vivo.

Authors:  Chunyu Li; Qi Wang; Shen Shen; Xiaolu Wei; Guoxia Li
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.